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The number of oral cancers associated with Human Papillomavirus (HPV) infection is increasing worldwide.
The purpose of this retrospective clinical trial is to investigate the relationship between genital and oral HPV
infection and to observe the possibilities of polymerase chain reaction (PCR) technique and the limitations
for oral HPV infection. The results of genital and oral HPV screening of 34 female patients and their partner,
and 14 single female patients were processed in a private practice in Budapest between 2012 and 2015.
After brush-biopsy sampling, HPV DNA identification and typing were performed using PCR technique. All in
all 164 samples were typed. HPV DNA was detected in 76 cases (48.20%). HPV was detected in 55 cases
from the genital samples (67%), and in 21 cases from the oral samples (25.6%). Genital HPV infection was
statistically significantly higher in women (79.2% vs 22,9%, p<0.001). Gender comparison of genital HPV
infection showed a statistically significant difference (79.2% for women, 50% for men, p = 0.006). In case
of genital HPV infection, the oral HPV infection of the same person is more frequent. In this study, the above
mentioned difference is significant for women and not significant for men. HPV16 is the HPV genotype
which was identified in the highest ratio(47.2%). PCR technique is capable of the detection of oral HPV
infection, but follow-up studies with higher case number , and questionnaire studies are needed to understand
HPV transmission more accurately.
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Human papillomavirus (HPV) infection is the most
common sexually transmitted disease in the world [1].
HPV infection is diagnosed in approximately 6 million
cases annually and 9.0-13.0 per cent of the world
population are infected. More than 100 genotypes of HPV
are known. There are low-risk groups (Low-Risk HPV, LR
HPV), such as HPV 6,11, which play a role in the aetiology
of benign lesions such as papilloma or condyloma
acuminatum. There are high-risk, oncogenic genotypes
(High-Risk HPV, HR HPV), such as HPV16,18 and 31, which
are responsible for the development of malignant lesions
(e.g., cervix carcinoma, oropharyngeal tumours).
Worldwide 6.7 per cent of all malignant tumours is due to
oncogenic HPV infection [2]. Malignant tumours
associated with HPV have a highest incidence on the cervix,
there 99.7 per cent of malignant lesions have oncogenic
HPV infection in the background [3]. Oncogenic genotypes
have been isolated from cancers of the vulva, vagina, penis,
anus and oropharyngeal and oesophageal cancers. Low-
risk genotypes HPV6 and HPV11 are most often present in
the mucus membranes causing papilloma and condyloma
acuminatum [4].
In Hungary according to the data of the Hungarian
Central Statistical Office the incidence of cervix carcinoma
is around 1500 cases per year and around 500 patients die
annually [3]. Hungary is the leader in incidence and
mortality in oropharyngeal cancer in Europe and is second
in the world in terms of men [5] . In terms of the numbers
in 2014 according to the National Cancer Registry 3765
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new cases of head and neck cancer  have been registered,
2688 men and 1077 women. According to data from the
Hungarian National Statistical Office in  2015 1157 male
and 303 female patients died of head and neck cancer.
The aetiology of oral cancer is multicausal. A distinction
between HPV positive and HPV negative tumours is made
in the literature. Classic etiologic factors include smoking,
excessive alcohol consumption, male gender, old age, poor
oral hygiene and mechanical irritation [6]. Due to current
sexual behaviour oral HPV infection is becoming more and
more common [7]. In the past 30 years the number of HPV
positive oral cancers has been on the rise [8, 9], especially
in the case of tonsil tumours, in 70 per cent of which
oncogenic HPV can be detected [10, 11]. The prevalence
of smoking has a decreasing tendency worldwide as well
as in Hungary, but the incidence of oral cancer is stagnating.
Oncogenic HPV-positive tumours are probably the
explanation for this discrepancy [8, 12]. Characteristics of
HPV related tumours include: location in the posterior
segment of the mouth (posterior tongue, soft palate, tonsils,
mesopharynx), the male:female ratio is typically 1:1,
patients are younger, presence of precancerous lesion is
rare. The prognosis of HPV-positive cancers is better,
recurrence is less frequent and they respond better to
radiotherapy [13]. The etiologic role of the oncogenic HPV
16 genotype is proven in oral cancer. HPV 16 isolated from
the back of the mouth can be considered a 13 fold risk
factor [14].
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HPV screening plays a very important role in the
prevention of cervix carcinoma as it successfully reduces
the incidence as well as the mortality of the disease [2].
Screening for oral cancer involves an annual dental checkup
visit where a thorough extraoral and intraoral examination
could identify suspect lesions. These are then biopsied in
oral surgery departments to provide a final diagnosis. There
are tools to aid the diagnosis of lesions invisible to the naked
eye [15], such as the VELscope based on the principles of
autofluorescence that can help differentiating between
healthy mucosa, hyperkeratotic mucosa and dysplastic
mucosa. These tools are not very widespread in dental
practice yet, but it has to be stressed that almost 90 per
cent or oral malignancies can be identified through
inspection [16]. The increasing proportion of HPV-positive
oral tumours requires HPV screening similar to
gynaecology. Based on the literature, similarly to genital
samples, a simple, non-invasive brush biopsy and
subsequent DNA Polymerase Chain Reaction (PCR) are
accepted as a means to detect and determine the type of
oral HPV infection [7, 17, 18].
The goal of the current paper is the retrospective study
of the genital and oral HPV screening of couples and female
patients presenting to a private practice in Budapest offering
dental and gynaecological care between 2012 and 2015.
Correlation between genital and oral HPV will be studied.
Experimental part
Materials and methods
The data presented in this study are from a selection of
patients who presented to a private practice in Budapest
between 2012 and 2015. In patients presenting for routine
gynaecological screening clinical and cytological
examinations were conducted as well as HPV typing.
Following this the patients requested screening for oral
cancer and HPV and, if they had a current partner then
their genital (glans penis, corona of  glans penis, external
urethral meatus) and oral screening for cancer and HPV.
Female patients who had any pathology on colposcopy or
cytology, who had a history of chemotherapy or
radiotherapy, who were immunosuppressed or received
aspecific immunostimulant treatment (Inosine Pranobex)
or who had been vaccinated for HPV were excluded from
the study. Similarly, male patients with any genital
abnormality, a histor y of chemo- or radiotherapy,
immunosuppression, aspecific immunostimulant
treatment (Inosine Pranobex) or HPV vaccination were
not included in the study. A total of 34 couples and 14 female
patients not living in a relationship were enrolled in the
study. In the case of couples the females’ mean age was
30.3 years (19-60 years), that of males was 35.7 years (21-
66 years), the mean age of ladies not living in a relationship
was 28.9 years (22-40 years). Patients were informed of
the possibility of oro-genital transmission of HPV and the
details of the examinations and the study and informed
consent was obtained.  One and the same practitioner
performed the genital examination in all cases and the
second practitioner performed all the oral examinations
and HPV sample collection. Oral examination involved
clinical screening for any mucosal lesion then a brush
biopsy was performed. The exfoliated cells collected were
placed into a transport medium of 1 mL PBS (phosphate
buffered saline) and were stored at -20°C until further
examination. Collection of genital and oral samples were
done at the same time for partners or within a week.
Sequences specific to HPV in clinical samples were
identified in the Department of Medical Microbiology of
the University of Debrecen. The exfoliated cells were
prepared for nucleic acid isolation with the following
method: 1 mL cell suspension was centrifuged at room
temperature for 5 min at 500 g and the sediment was
suspended in 200 µL PBS solution. DNA isolation was don
with the help of the innuPrep Viral RNA/DNA kit (Analytik
Jena, Jena, Germany) following the manufacturer1s
protocol. Briefly, 200µL Carrier mix-containing CBV lysis
buffer and 20 µL proteinase K were added to 200 µL of cell
suspension, and it was incubated at 70°C for 10 min.
Following incubation 400 µL SBS binding buffer is added to
the samples and vortexed and then was added to the Spin
Filter column and centrifuged for 1 min at 10000 g.
Following this the columns were washed with once 500
µL HS, and twice with 650-650 µL LS buffer and between
each step the samples were centrifuged for 1 min at 10000
g. After this the columns were further centrifuged for 5
minutes at 10000 g to remove the buffer. Nucleic acid was
eluted from the columns with 60 µL of RNAse-free water
preheated to  70°C; the columns were incubated at room
temperature for 2 min and then centrifuged at 8000 g for
one min. DNA was stored at -20°C until further processing.
The quality of the DNA was checked using a polymerase
chain reaction (PCR) specific to the human β-globin gene.
HPV-specific sequences were detected using MY/GP
consensus nested PCR that is specific to the conservative
L1 gene of mucosal HPV that is usable to detect these
HPV genotypes [19]. HPV genotype detection was done
either with restriction fragment length polymorphism
(RFLP) of MY PCR products [20] or with the sequencing of
GP amplimers (Macrogen, Amsterdam, The Netherlands).
In cases when a mixed infection was suspected and the
MY PCR yielded a positive result, genotypes were identified
with the help of a GenoFlow HPV array test kit (DiagCor,
Kowloon Bay, Hong Kong) following the manufacturer’s
protocol. In the case of HPV6, HPV11, HPV16, HPV18,
HPV31 and HPV33 genotypes the results of genotyping
were confirmed with type-specific PCR as well[21]. In a
few cases  HPV genotyping was unsuccessful due to the
low number of copies. These cases were classified as
slightly positive, not identifiable (NI).
In statistical calculations frequency tables were used
to demonstrate genital and oral HPV prevalence in women
and men and the prevalence of HPV infection in partners
was also analysed in couples. The various groups were
analysed using the Chi square and Fisher’s exact tests. For
the statistical analysis we used IBM SPSS statistics 23
software (IBM Corporation).
Results and discussions
The stomatooncological screening of 82 patients did
not reveal any precancerous or malignant lesion.
A total of 34 couples had genital and oral HPV screening
resulting in 136 samples. An additional 14 female patients
had genital and oral HPV screening who did not live in a
relationship. This yielded another 28 samples. Thus a total
of 164 samples were studied. HPV DNA was demonstrated
in  76 cases (46.30%). In females presenting with their
partners HPV DNA was detected in 28 genital samples
(82.40%), in females without a partner 10 cases were
positive for HPV DNA from genital samples (71.40%), thus
HPV DNA was detectable in a total of 34 out of 48 female
genital samples (79.20%). Out of the 34 male patients HPV
DNA was detectable in 17 genital samples(50%).  Genital
HPV infection showed a statistically significant difference
(p<0.01) between the two sexes (table 1).
In 21 of the oral samples HPV DNA was detected
(25.60%), in 9 of the ladies with partners (26.50%), and in
2 of the ladies not in a relationship (14.30%), thus 11 females
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(22.90%), and 10 males (29.40%) were infected. It was
found that genital HPV infection was present in a higher
percentage both in women and in men than oral infection
(table 2), which difference was significant in the case of
women and not significant in the case of men (79.2% vs
22.9%, p<0.001).
It could be seen that in the case of patients with genital
HPV infection oral HPV infection is more common than in
the case of no genital HPV infection. This difference is
32.14% vs. 0% in females and 35.50% vs. 23.50% in males
(table 3.), which is not significant statistically.
In terms of oro-genital transmission it could be seen
(table 3) that the partners of males with a genital HPV
infection had a higher percentage of oral HPV infection
than those of genitally HPV negative males (17.60% vs.
35.30%, p=0.438). In the case of women, however,
surprisingly,  the partners of genitally HPV negative women
had a higher rate of oral HPV infection than partners of
HPV positive women (50% vs. 25%, p= 0.328), although
the difference was not significant. In terms of genital
transmission there was no difference between the partners
of HPV positive vs. negative women (50% vs. 50%) or HPV
positive vs. negative men (82.40% vs. 82.40%) either as far
as genital HPV infection is concerned.
There is statistically significant difference (p=0.023)
between men and women, however, in terms of the HPV
infection of the partner of genitally HPV positive patients
(table 4.): the genital infection rate of the partners of males
was 82.4% (i.e. the genital HPV infection of female
partners), for women it was 50% (genital HPV infection of
male partners). This was similar in oral samples as well,
but the difference was not significant (35.30% vs 25%,
p=0.461).
The 76 samples positive to HPV DNA show the following
genotype distribution: in the case of 5 samples LR HPV
has been identified (genotypes 11, 53, 57, 61, 81), in a total
of 27 cases HR HPV monoinfection has been detected, out
of which 15 were the genotype HPV16, 3 were HPV 56 and
another 3 were HPV 66, the other 6 HRs were 18, 31, 33,
45, 51, 58. A mixed infection was seen in four cases: HPV
16/6, 45/68, 16/51, 31/39/45, all of which contain an HR
genotype. HPV was not identifiable from 40 samples (HPV
NI).
Table 2
HPV  INFECTION ACCORDING TO LOCALISATION IN
FEMALES AND MALES.  Significant differences are
marked with *
Table 1
GENITAL AND ORAL HPV INFECTION RATE BASED
BY SEX. Significant differences are marked with *
Table 3
HPV TRANSMISSION STUDIES
BETWEEN MALES AND
FEMALES.  Significant
differences are marked with *
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The distribution of HPV LR, HPV HR, HPV 16 and HPV NI
genotypes according to infection site and gender is shown
in table 5.
Examining the genotypes it was found that out of the 38
genital HPV infections in women 23 had HR HPV (60.50%),
out of which HPV 16 DNA (44%) was identified in 10 cases,
which is the most common of the identified genotypes. In
males with genital HPV DNA positivity  HR HPV-DNA was
identified in 4 cases (23%), out of which 3 were HPV 16
(75%). Out of the 21 HPV positive oral samples 4 (5.25%)
were found to be HR HPV, all of which was HPV 16 (100%).
Two of these patients were male and two female. LR HPV
DNA was only found in genital samples, in a total of 5
cases, 4 in women (10.5%) one in a man (5.9%). Out of
the 76 HPV DNA positive samples the genotype could not
be identified (HPV NI) in 40 cases (52%), the lowest ratio
(29%) was amongst female genital samples (n=11), the
highest ratio (81.8%) was amongst female oral samples
(n=9).
PCR Technique is an important element in assisting the
early diagnosis of human papillomavirus and also in the
diagnosis and the treatment of periodontal disease. [32]
The causative aetiological role of HPV in cervical cancer
has been known since 1983 and HPV can be detected in
almost 100% of the malignancies in the region [2]. High
risk HPV DNA can integrate into mucosal cells, thus viral
genes E1 and E2 are damaged. These two genes are
responsible for the regulation of the expression of viral
oncogenes E6 and E7 which play a role in the inhibition of
cellular tumour suppressor genes (p53, pRB). The outcome
is the over expression of the oncoproteins E6 and E7 can
leads to the malignant transformation of the infected cell
[22] . Due to changed sexual habits HPV appears in the
Table 4
COMPARISON  OF THE HPV INFECTION OF
PARTNERS OF  GENITALLY HPV POSITIVE MEN AND
WOMEN. Significant differences are marked with *
Table 5
 HPV INFECTION ACCORDING TO SEX AND LOCALISATION. In the HR HPV group HPV 16 is shown in parenthesis
Comparison of  genotype distributions within each group using the Bonferroni correction.
a means significant difference between LR HPV and HR HPV groups.
b means significant difference between HR HPV and NI HPV groups.
c means significant difference between LR HPV and NI HPV groups
1.This category is not used in comparisons because its column proportion is equal to zero or one.
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oral cavity via oro-genital transmission, where it persists or
can cause the development of benign of malignant lesions.
The lesions with HPV as an aetiological factor in the oral
cavity can be benign, such as papilloma, condyloma
acuminatum, precancerous lesions, such as leukoplakia,
or malignant, squamous cell carcinoma. HPV 16 is thought
to be responsible for the development of HPV related
malignancies. Kreimer et al. (2010) concluded in their
review that HPV DNA could be identified in 35.6% of
oropharyngeal tumours, out of which 87% could be
identified as  HPV 16 [23]. The presence of the  HPV 16
genotype in the oral cavity can be considered a risk factor
of oral malignancy, similar to smoking that can increase
the risk of oral cancer by 13 times [14]. In the current study,
HPV 16 was the most often identified out of the high risk
HPV group (HR- HPV), that could be isolated from almost
half of the female genital samples (10 cases, which result
is comparable to those obtained by Tatar et al [24]. Out of
HR HPV  genotypes HPV 16 was identified in three-fourths
of the male genital samples (3 cases), and in each of the
oral samples (4 cases, 2 male, 2 female).
Currently three methods are used in clinical diagnostics
to identify HPV and Ebola virus desease [33].  These are
methods based on polymerase chain reaction (PCR),
fluorescence in situ hybridisation (FISH), and
immunohistochemical staining to identify the p16INK4A
marker [25]. FISH is a method with a sufficient sensitivity,
but its disadvantage is that a DNA fragment of the HPV
genotype to be identified needs to be known. The  p16INK4A
immunohistochemical stain is suitable to identify HR-HPV
positive malignant lesions by demonstrating actually
dysplastic cells. Its disadvantage is that it cannot identify
non-malignant cells infected with HPV. It cannot be used
to identify LR-HPV infection. PCR is a high sensitivity
technique that can be used to study samples from a variety
of tissues, which combined with oral cell extraction  (cf.
cytobrush) is an accepted method of oral HPV
screening[26, 27]. The high sensitivity of PCRmakes it
possible to identify HPV DNA present in a low copy number.
Szarka et al. (2009) studied the HPV DNA copy numbers in
samples from malignant oral squamous cell tumours, oral
precancerous lesions and from exfoliated cells of clinically
healthy oral mucosa from the same patients as well as
from healthy individuals and found that the copy number
of the virus had a correlation with the severity of the lesions
[19]. Besides they also studied the number of copies of
HPV DNA in genital and oral samples and found that in
women suffering from HSIL the copy of the virus DNA was
significantly higher in the genital tract than in their partners’
genital samples, but the viral load of the oral mucosa did
not show a significant difference according to sex[24]. It
is important to determine what viral load has a clinical
relevance and a prognostic value in predicting the
development and prognosis of oral lesions, which would
necessitate further long term follow-up studies in large
populations.
In the present study the correlation between genital and
oral HPV infection was studied in the case of 34 couples
and 14 single women. Out of the 48 female participants
HPV DNA was identified in the genital sample in 38 cases
(79.20%) and a total of 11 cases (22.90%) of oral HPV
positivity were identified, therefore genital HPV infection
in women is significantly more common than oral HPV
infection  This is in line with the data published by Meyer et
al.[25], who compared the genital and oral HPV status of
129  women and found that 54.3% had genital HPV DNA
positivity 5.4% had oral HPV infection. Almost a third of
HPV positive oral samples originated from women with
genital HPV infection and no HPV DNA was found in the
oral samples of women who had no genital HPV infection,
which correlates with a number of studies[24, 25, 28, 29].
Meyer et al. (2014) found HPV DNA in the oral samples of
5.7% of women with genital HPV infection  and in 5.1% of
genitally HPV negative women. Giraldo et al. [29]
compared the oral HPV status of 70 genitally HPV positive
women with that of 70 genitally HPV negative women.
Their results showed that oral HPV prevalence was
significantly higher in genitally HPV DNA positive patients
(37.1%), than in genitally HPV DNA negative patients
(4.3%). Furthermore 89.7% of orally HPV infected patients
had genital HPV infection, too, which was 100% in the
present study. In the present study genital HPV infection
was also more common in men than oral HPV infection
(50% vs. 29.4%), though the difference is not statistically
significant. In the women studied the prevalence of genital
infection was significantly higher than in men. The
prevalence of oral HPV infection was higher in men than
women, but this difference was not statistically significant.
The person with genital HPV infection had a higher chance
of oral HPV infection in both genders (table 3.). This must
no be forgotten in interdisciplinary communications as
women participate in genital HPV screening more often
than oral screening if HPV positive patients were informed
of the necessity of oral screening (both for the patient and
her partner) then an important risk group could undergo
stomatooncological screening. Upon studying cross
infection it can be stated that genitally HPV infected men’s
partners have a higher risk of oral infection than partners of
genitally HPV negative men (35.3% vs. 17.6%). Furthermore
partners of genitally HPV infected men had a higher ratio
of genital and oral HPV infection than partners of genitally
HPV infected women (table 4.). The incidence of genital
lesions with an HPV related aetiology is low, just as genital
HPV screening, therefore persistent cases of HPV are
difficult to identify and continue to threaten the genital and
oral health of their partners. Based on these considerations
the routine genital screening of males for HPV and the
adequate management of these cases seem to gain
importance. This could theoretically reduce the number of
HPV related oral malignancies. Carrying this thought further
the extension of HPV vaccination to boys might have a
preventative value [30].
 Tatar et al. [24]  found a lower percentage of genital
HPV infection in males and genital infection was more
common than oral infection both in male and females.
The observation of the present study are in agreement with
this. The lower ration of oral HPV prevalence could be due
to the presence of antimicrobial components in the oral
cavity  eg. cytokines,  lactoferrin, lysozyme, immuno-
globulin A, therefore the contact time between the virus
and the oral mucosa is reduced. The actual effectivity of
these protected mechanisms is not yet clear [25]. The
difference in genital HPV infection between sexes could
be explained by the lack of the transformation zone
(preferable to HPV) in men. No such zone is found in the
oral cavity either. This is a zone in the cervix where the
squamous epithelium of the orifice and the columnar
epithelium of the cervical meet. The transformation zone
(or junctional zone) develops at the movement of the
meeting zone between squamous cells and columnar
cells. Its extent and location are dependent on age.
Physiologically this region is in constant movement,
regeneration can be observed. HPV infection always
happens through the epithelial wounds of this region or at
the squamo-columnar junction [31]. A further explanation
could be that in the male genital tract and in the oral cavity
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the dynamics of HPV elimination is not entirely clear and
data are scarce. In order to determine this further studies
are necessary with large study populations and long follow-
up times.
 Meyer et al. [25] performed genital and oral HPV
screening of 129 female patients, HPV DNA was found in
oral samples in 7 cases (5.4%). LR-HPV had a higher ratio
(n=4, 51.7%), than HR-HPV (n=3, 42.9%). In the present
study oral HPV DNA was detected in a higher percentage,
in 21 cases (25.60%) and 4 out of these(19%)  were HR
HPV (HPV 16) and 17 were  HPV NI (81%). No low-risk
HPV (LR-HPV) group was detected in oral samples. In most
of the 76 HPV DNA positive samples (40 cases - 52%) the
genotype could not be identified (HPV NI). Out of the 55
genital HPV positive samples 23 cases were HPV NI (42%),
and out of the 21 oral samples 17 cases were HPV NI
(81%), lowest ratio of HPV NI was found amongst female
genital samples (29%). This ratio is much higher in male
genital samples (71%) and even higher in oral samples
where it was 80% for males and 82% for females. This
result corresponds to those reported by Tatár et al.[24],
which state that the average number of copies from
cervical samples is at least a magnitude higher than in any
other localisation that plays a basic role in genotype
identification due to the sensitivity of the typing
methodology. According to another explanation is mixed
infection that can also limit genotype identification. As HPV
NI results can potentially contain HR HPVs, clinically these
should be considered high risk and should be managed
accordingly (observation, recall, treatment).
In terms of couples there was a single case where the
same genotype could be identified from both the genital
and oral samples and it was a HPV 16 volt (3%).  Meyer et
al. identified the same HPV genotype from female genital
and oral samples and it was a LR HPV 54 (0.8%). Apart
from the single case discussed above there were two cases
in the current study where HPV DNA could be identified
both from female and male genital and oral samples but in
both cases a genotype could only be determined from the
female genital sample (HR HPV 58, and HR HPV 16), the
genotype could not be identified in any of the other samples.
Thus, out of the 34 couples a total of 3 cases (8.8%) were
found  where HPV DNA could be identified in all 4 samples.
In the case of couples the differences in HPV genotype in
the genital and oral samples are important in
communications. It has to be stressed that differences in
genotypes or in positivity do not suggest infidelity as the
susceptibility to infection and the dynamics of elimination
differ from person to person.
Conclusions
 Genital HPV infection suggests a potentially higher risk
for oral HPV infection in both sexes than in HPV negative
patients.
HPV positive males have a higher risk of genital and oral
infection than partners of HPV positive females. This has a
preventative importance in interdisciplinary
communication due to persisting infection, common in
men.
Oral HPV screening can be done at the same time as
stomatooncological screening and is non-invasive.
PCR routinely used in laboratory diagnostics is useful in
oral HPV screening  because of the lower number of HPV
DNA copies than in the genital region.
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